| scholarly article | Q13442814 |
| P50 | author | William Douglas Figg, Sr. | Q16195062 |
| Alex Sparreboom | Q71780219 | ||
| Seth M Steinberg | Q92007107 | ||
| Tristan M Sissung | Q104284500 | ||
| P2093 | author name string | Dirk Behringer | |
| Klaus Mross | |||
| Stephan Mielke | |||
| P2860 | cites work | Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients | Q28345475 |
| Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions | Q33183268 | ||
| Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites | Q33832954 | ||
| Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 | ||
| Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs | Q34059522 | ||
| The MDR1 (ABCB1) gene polymorphism and its clinical implications | Q35817004 | ||
| Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h | Q40551884 | ||
| Taxol transport by human intestinal epithelial Caco-2 cells. | Q41043920 | ||
| Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype | Q41592100 | ||
| Protection of hematopoietic stem cells from chemotherapy-induced toxicity by multidrug-resistance 1 gene transfer. | Q41597920 | ||
| G2677T and C3435T Genotype and Haplotype Are Associated With HepaticABCB1(MDR1) Expression | Q58869653 | ||
| The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells | Q74127572 | ||
| Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability | Q95805177 | ||
| P433 | issue | 17 | |
| P921 | main subject | peripheral neuropathy | Q945238 |
| P304 | page(s) | 2893-2896 | |
| P577 | publication date | 2006-09-06 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia | |
| P478 | volume | 42 |
| Q36243420 | A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. |
| Q36447729 | A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma |
| Q37297173 | ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel |
| Q90394854 | ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy |
| Q38551666 | Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review |
| Q40208965 | Association analysis of three ABCB1 (MDR1) gene variants (C1236T, G2677A/T and C3435T) and their genotype/haplotype combinations with the familial Mediterranean fever |
| Q37055326 | CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel |
| Q35212672 | Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. |
| Q37826427 | Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence |
| Q37659699 | Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. |
| Q43058277 | Chemotherapy-induced peripheral neuropathy: an unresolved issue |
| Q60750355 | Chemotherapy-induced peripheral neurotoxicity |
| Q37896345 | Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics |
| Q36043023 | Efflux transporter variants as predictors of drug toxicity in lung cancer patients: systematic review and meta-analysis. |
| Q21261276 | Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study |
| Q34633385 | Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy |
| Q33422082 | Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer |
| Q34663656 | Genetic variation: effect on prostate cancer. |
| Q28943314 | Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy |
| Q38120289 | Germline pharmacogenetics of paclitaxel for cancer treatment |
| Q37854536 | Haematological toxicity of clozapine and some other drugs used in psychiatry. |
| Q34781769 | Impact of ABCB1 allelic variants on QTc interval prolongation |
| Q39702921 | Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer |
| Q38414396 | Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature |
| Q35945680 | Informative gene network for chemotherapy-induced peripheral neuropathy |
| Q36545157 | Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy |
| Q28534786 | Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial |
| Q28271570 | Ixabepilone for the treatment of solid tumors: a review of clinical data |
| Q37788732 | Level of evidence for therapeutic drug monitoring of taxanes |
| Q37662576 | Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review. |
| Q50522019 | Microtubule-targeting drugs and personalization of cancer treatment. |
| Q34458581 | Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer |
| Q91806734 | P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients |
| Q38817753 | Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. |
| Q37346198 | Pharmaco(epi)genomics in ovarian cancer |
| Q36719659 | Pharmacogenetics and oncology treatment for breast cancer |
| Q38222511 | Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins. |
| Q38242601 | Pharmacogenetics of membrane transporters: a review of current approaches. |
| Q37641869 | Pharmacogenetics of membrane transporters: an update on current approaches |
| Q38065218 | Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity. |
| Q37684533 | Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy |
| Q37967607 | Pharmacogenomics in neurology: current state and future steps |
| Q46563276 | Pharmacogenomics of importance for paclitaxel chemotherapy |
| Q37736449 | Pharmacogenomics of paclitaxel |
| Q43280939 | Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy |
| Q36885663 | Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel |
| Q30433670 | Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study |
| Q33953209 | Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). |
| Q43496569 | Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity |
| Q37253554 | Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma |
| Q36877796 | Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. |
| Q46119122 | Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. |
| Q34774854 | Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance |
| Q50526560 | Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. |
| Q46800256 | SNPs and taxane toxicity in breast cancer patients |
| Q53135936 | SNPs associated with activity and toxicity of cabazitaxel in patients with advanced urothelial cell carcinoma. |
| Q55497899 | SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. |
| Q92684874 | Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events |
| Q34390370 | Taxane pathway |
| Q45759415 | Taxane-Induced Peripheral Neurotoxicity. |
| Q36364762 | Taxanes for the treatment of metastatic breast cancer |
| Q24289538 | Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance) |
| Q36216741 | The ABCB1 3435 T allele does not increase the risk of paclitaxel-induced neurotoxicity |
| Q26749954 | The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment |
| Q37735146 | Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy |
| Q38086872 | Tubulin: an example of targeted chemotherapy |
| Q37663396 | Uptake carriers and oncology drug safety |
| Q36035404 | Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel |
Search more.